Many people lose their battle against cancer because of late detection, mostly in the last few stages of the deadly disease. This leaves them with little to no chance of survival. ERLY Sign company has come up with a revolutionary oral cancer detection kit that helps one self-diagnose in an easy, affordable, painless, and accurate manner. Read on further to know more about this company and its miraculous testing kit.
About ERLY Sign
Erly Sign emerges as an accessible, precise, and pain-free solution for the early detection of Oral Cancer. The innovative approach involves a non-invasive process, utilizing only an individual’s early morning saliva, eliminating the need for pricks, needles, or blood. Conveniently performed at home, the comprehensive kit, reports, and consultations are delivered directly to the doorsteps, ensuring a hassle-free experience. This time-efficient alternative spares individuals from waiting for appointments or enduring queues for testing, making it a practical choice. Erly Sign’s commitment to affordability not only eases the financial burden but also distinguishes it from other costly lab tests.
Erly Sign employs a risk assessment methodology, categorizing results into Low, Moderate, or High risk. A Low Risk outcome signifies a clean bill of health, prompting users to embrace a wholesome lifestyle. For those seeking additional guidance, a complimentary consultation with the Nutritionist is available to tailor a personalized diet plan and workout regime. It is advised to maintain a healthy distance from tobacco-related products and excessive alcohol consumption for overall well-being. Erly Sign stands out as a user-friendly, preventive healthcare solution, offering peace of mind through early detection and proactive health management.
How it Works?
Erly Sign simplifies oral cancer detection with its user-friendly Saliva Collection Kit, designed for ease and effectiveness.
Preparation Steps:
To ensure the freshness of the morning saliva required for testing, users are advised not to eat, drink, or chew before contributing their sample. Additionally, refraining from tooth brushing or mouthwash, a simple rinse with water suffices before providing saliva.
Sequential Steps:
Login: Users begin by visiting www.erlysign.com to register their test kit using the unique kit number on the package, preventing any mismatches during result interpretation.
Spit: Following registration, users follow provided instructions to spit into the provided tube, ready to be mailed back to Erly Sign’s lab using the pre-paid package.
Analysis and Report Delivery: Upon receiving the saliva sample, Erly Sign conducts a thorough analysis, promptly sending reports to the registered email address. Simultaneously, users receive a notification on their registered mobile number.
Warnings and Precautions:
Erly Sign prioritizes safety, advising users to keep the kit away from children, wash with water if the stabilizing liquid contacts eyes or skin, and strictly avoid ingestion.
Interpreting Results:
Users are encouraged to refer to the “What’s Next” booklet, providing guidance on interpreting results and making informed decisions about the subsequent steps based on the outcome. Erly Sign’s commitment to user-friendly, preventive healthcare is evident in its seamless process and comprehensive support provided within the kit.
Who is at Risk?
The susceptibility to oral cancer knows no exclusions, with evolving factors and lifestyle choices playing pivotal roles. One such prevalent risk factor lies in the consumption of tobacco and betel nut/areca nut (supari) in diverse forms—ranging from cigarettes, beedi, pipes, cigars, to the habit of chewing (smokeless) tobacco.
Additionally, the practice of keeping a tobacco quid inside the mouth and indulging in paan with betel nut/areca nut (supari) further emerges as contributing factors to this health concern. Understanding these risk elements sheds light on the importance of awareness and preventive measures in maintaining oral health.
What is Oral Cancer?
Oral cancer stands as a significant and escalating global public health challenge, persisting as the primary cause of death stemming from oral diseases on a global scale. Encompassing malignancies affecting the vermillion borders of the lips and all surfaces of the oral cavity, including the anterior two-thirds of the tongue, these cancers predominantly manifest as squamous cell carcinomas, presenting a formidable threat due to their high lethality, incapacitating nature, and disfiguring impact.
Historically, the mortality rate associated with oral cancer remains notably elevated, primarily attributed to delayed-stage diagnosis and intervention. Presently, the majority of patients undergo detection through visual examinations and/or when symptomatic, often reaching a late stage at this point. Consequently, oral cancer frequently goes unnoticed until it progresses to the extent of metastasis, underscoring the critical importance of early detection and proactive intervention in addressing this formidable health issue.
Founder and his Vision
Shubhendra Singh Thakur, co-founder and CEO of ERLYSIGN, is a 29-year-old entrepreneur renowned for his proficiency in machine development, showcased through various innovative gadgets during his engineering days. The pivotal shift to the healthcare industry was deeply personal, driven by his mother’s kidney condition diagnosis. Spending significant time in hospitals, particularly observing oral cancer patients and their struggles, ignited Shubhendra’s determination to transform the landscape of cancer healthcare.
In 2020, Shubhendra, alongside his biochemistry professor, Dr. Begde, established ERLYSIGN, India’s pioneering biotechnology startup specializing in early-stage diagnostic solutions and medical devices for the early detection of multiple cancers. Motivated by the vision to address the challenges he witnessed, ERLYSIGN introduced India’s first testing kit, ensuring non-invasive and painless early detection through a saliva sample. Shubhendra’s commitment extends to providing quick results for precancerous conditions even before visible tumors or lesions appear in the oral cavity.
Nominated for the 2019 Rex Karmaveer Chakra Award and the Karmaveer Global Fellowship by ICONGO and the United Nations, Shubhendra emphasizes the impact of cancer, a disease surpassing pandemics in its toll. His words resonate with strength and resilience, encouraging those battling cancer not to give up. Shubhendra underscores the progress in cancer prevention tools and the transformative potential of early detection and personalized therapeutic approaches. His vision extends to a collaborative effort, envisioning a world without cancer through collective action and awareness.
The Team Behind ERLY Sign
The dynamic team behind ERLYSIGN, led by co-founders Dr. Deovrat Begde and Shubhendra Singh Thakur, epitomizes a blend of expertise and passion. Dr. Begde, with over 15 years of research and teaching experience in Biochemistry and Biotechnology, holds an Indian National Patent and numerous well-cited research articles. Shubhendra, a versatile entrepreneur with a Biology degree and a specialization in Clinical Trials, has spearheaded revolutionary solutions, including safety wearables and campus networking applications.
The research team, consisting of Pooja Awasthi, Arti Payasi, Dr. Sunita Bundale, and Dr. Arpita Parakh, complements the leadership with their diverse backgrounds in biochemistry, microbiology, and bioinformatics. Their collective dedication drives ERLYSIGN’s mission to revolutionize early-stage cancer detection, exemplifying a harmonious fusion of expertise and commitment.
The Journey So Far
Since its inception in 2018, ErlySign has made remarkable strides, evolving from an idea to a widely accepted cancer detection solution. Validated by American oncology specialists and endorsed by US-based oncologists, ErlySign is actively engaged in large-scale clinical trials with Health Care Global Ltd, Southeast Asia’s leading cancer care network.
Securing funding from renowned healthcare investors in 2019 and a subsequent seed round in 2021, ErlySign’s achievements include recognition as the Best Early Stage Cancer Detection Startup 2021 by Global Health & Pharma News and acknowledgment as one of Asia’s most prestigious growing brands by BARC Asia. Best Startup Asia also honored ErlySign as the best medical device firm in India.
